Findings reveal that monitoring plasma concentrations of rifampicin and isoniazid in tuberculosis may optimize treatment outcomes, indicating the importance of acetylator status.
Abnormal concentrations of rifampicin and isoniazid are prevalent and a major concern. Acetylator status influences plasma concentrations of rifampicin and isoniazid. Hence, determining acetylator status and performing TDM could be instrumental in optimizing and improving TB outcomes.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: